Nidogen-2: a new serum biomarker for ovarian cancer.
Nidogen-2: a new serum biomarker for ovarian cancer.
复制标题
DOI：
10.1016/j.clinbiochem.2009.10.012
复制
发表时间：
2010-03
影响因子：
2.8
通讯作者：
Diamandis EP
中科院分区：
文献类型：
--
作者：
Kuk C;Gunawardana CG;Soosaipillai A;Kobayashi H;Li L;Zheng Y;Diamandis EP
新的卵巢癌生物标志物适用于疾病的早期诊断、预后或监测，可以改善患者的管理和预后。用免疫分析法检测了100例健康妇女、100例妇科良性疾病患者和100例卵巢癌患者血清中Nidogen-2的含量。正常组和良性疾病组的血清NIDGEN-2浓度差异无统计学意义(中位数分别为13.2g/L和12.1gg/L)。而卵巢癌患者血清Nidogen-2浓度升高(中位数18.6μg/L；p<；0.0001)。Nidogen-2和CA125在卵巢癌浆液性组织类型和晚期疾病中升高较多。Nidogen-2与CA125浓度呈强相关。ROC曲线分析表明，Nidgen-2的曲线下面积(AUC)为0.73~0.83，而CA125更好(AUC为0.87~0.99)。这两个标记之间没有互补性。Nidogen-2是一种与CA125密切相关的卵巢癌新生物标志物。
New ovarian cancer biomarkers suitable for early disease diagnosis, prognosis or monitoring could improve patient management and outcomes. Nidogen-2 was measured by immunoassay in serum of 100 healthy women, 100 women with benign gynecological conditions and 100 women with ovarian carcinoma. Serum nidogen-2 concentration between normal and benign disease patients was not different (median, 13.2 and 12.1 μg/L, respectively). However, nidogen-2 concentration in serum of ovarian cancer patients was elevated (median, 18.6 μg/L; p<0.0001). Both nidogen-2 and CA125 were elevated more in serous histotypes of ovarian cancer and late state disease. Nidogen-2 and CA125 concentrations were strongly correlated. ROC curve analysis for nidogen-2 had an area under the curve (AUC) ranging from 0.73 to 0.83 but CA125 was superior (AUC ranging from 0.87 to 0.99). There was no complementarity between the two markers. Nidogen-2 is a new biomarker for ovarian cancer which correlates closely with CA125.
登录
查看更多内容
影响因子：
7
作者：
Kuk, Cynthia;Kulasingam, Vathany;Diamandis, Eleftherios P.
通讯作者：
Diamandis, Eleftherios P.
影响因子：
11.2
作者：
Bassi, DE;De Cicco, RL;Klein-Szanto, AJP
通讯作者：
Klein-Szanto, AJP
影响因子：
64.5
作者：
Sherwood, DR;Butler, JA;Sternberg, PW
通讯作者：
Sternberg, PW
影响因子：
5.6
作者：
Kohfeldt, E;Sasaki, T;Timpl, R
通讯作者：
Timpl, R
影响因子：
11.4
作者：
MAYER, U;NISCHT, R;TIMPL, R
通讯作者：
TIMPL, R